Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 475 | 896 | 14,949 | 1,033 | 1,173 |
| Cost of Goods | 551 | 619 | 528 | 1,567 | 720 |
| Gross Profit | -76 | 277 | 14,421 | -534 | 453 |
| Operating Expenses | 9,267 | 9,750 | 10,854 | 11,861 | 22,026 |
| Operating Income | -8,792 | -8,854 | 4,095 | -11,828 | -20,853 |
| Interest Expense | 0 | 949 | 898 | 1,154 | 1,169 |
| Other Income | -1,155 | 0 | 0 | 0 | -20 |
| Pre-tax Income | -9,947 | -9,803 | 3,197 | -12,982 | -22,042 |
| Income Tax | 8 | 9 | 5 | 5 | 9 |
| Net Income Continuous | -9,955 | -9,812 | 3,192 | -12,987 | -22,051 |
| Net Income | $-9,955 | $-9,812 | $3,192 | $-12,987 | $-22,051 |
| EPS Basic Total Ops | -204.00 | -255.86 | 80.95 | -328.57 | -559.52 |
| EPS Basic Continuous Ops | -203.81 | -255.93 | 80.74 | -328.92 | -558.54 |
| EPS Diluted Total Ops | -204.00 | -255.86 | 80.95 | -328.57 | -559.52 |
| EPS Diluted Continuous Ops | -203.81 | -255.93 | 80.73 | -328.92 | -558.54 |
| EPS Diluted Before Non-Recurring Items | -202.38 | -247.62 | 80.95 | N/A | N/A |
| EBITDA(a) | $-8,409 | $-8,470 | $4,483 | $-11,462 | $-20,436 |